Effects of Varenicline on Plasticity in Schizophrenia

Schizophrenia Clinical Trial

— VAR-PAS  

Official title:

Effects of Varenicline on Cortical Neuroplasticity and Working Memory in Patients With Schizophrenia and Healthy Controls

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT01934023
• Other study ID #: 214-2012
• Secondary ID: Wi172662
• Status: Completed
• Phase: Phase 2
• First received: August 27, 2013
• Last updated: August 24, 2015
• Start date: September 2013
• Est. completion date: August 2015

Study information

• Verified date: August 2015
• Source: Centre for Addiction and Mental Health
• Contact: n/a
• Is FDA regulated: No
• Health authority: Canada: Health Canada
• Study type: Interventional

Clinical Trial Summary

This laboratory pilot study will explore the effects of varenicline tartrate on long-term potentiation (LTP)-like mechanisms of (1) the motor cortex and (2) the dorsolateral prefrontal cortex (DLPFC) and working memory in non-smoking patients with schizophrenia and healthy controls using a Paired Associative Stimulation (PAS) method. The present study will use this novel PAS method to evaluate the effects of five doses of varenicline (Champix) 0.5 mg BID treatment on neuroplasticity changes and working memory in 28 non-smokers with schizophrenia and 28 non-smoking controls in a placebo-controlled, double-blinded, cross-over design. The hypothesis is that varenicline will increase LTP-like facilitation of the DLPFC as compared with placebo in patients with schizophrenia, with less or a null effect in healthy controls. Likewise, it is hypothesized that varenicline will specifically improve working memory in patients with schizophrenia as compared with placebo and healthy controls. We Hypothesize that: 1.Patients with Schizophrenia(SCZ) will have reduced cortical LTP and impaired working memory compared to healthy controls 2. Sub-chronic varenicline challenge will attenuate the cortical LTP and working memory deficit in patients with SCZ. 3.Reversal of the cortical LTP deficit by varenicline in patients with SCZ will be associated with improvement in working memory.

Description:

The experimental laboratory study will be designed as a randomized, double-blinded, placebo-controlled acute treatment trial. Paired Associative Stimulation (PAS)-induced cortical evoked activity and Working Memory (WM) will be assessed in healthy non-smokers and non-smokers with SCZ, after five doses of varenicline tartrate (0.5 mg/dose) and placebo treatment. PAS will be induced by pairing transcranial magnetic stimulation with peripheral nerve stimulation, 25 msec apart (hence PAS-25). In part 1, motor cortex plasticity will be assessed as changes in motor evoked potential comparing pre to post PAS up tp 120 min after PAS. In part 2, DLPFC evoked cortical activity will be assessed using EEG comparing pre to post PAS. Effects of varenicline and PAS-25 on WM will evaluated using a computerized N-back task, assessed directly before the PAS testing. The whole experimental session will be repeated for each participant twice: once with varenicline tartrate treatment and once with placebo treatment, two weeks apart.

Recruitment information / eligibility

• Status: Completed
• Enrollment: 24
• Est. completion date: August 2015
• Est. primary completion date: August 2015
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Both
• Age group: 18 Years to 55 Years

Eligibility

Inclusion Criteria (Healthy subjects and Scz):

• Non-smoker or past smoker, abstinent for at least the last 1 year

• Females with potential childbearing must have a negative serum pregnancy test at inclusion.

• Ability and willingness to speak English

• Willingness to provide informed consent

• Adequate hearing and visual capacity, or corrected by visual/ hearing aid, right handedness.

INCLUSION Criteria (Scz Only):

• Diagnosis of schizophrenia

• Stable psychotropic drug treatment for at least the past 4 weeks

• Clinically stable for the past 3 months.

Exclusion Criteria (healthy subjects and SCZ):

• Current smoker or abstinent smoker for less than 1 year

• Current history of drug abuse disorder or current elicit drug use

• Current or past history of neurological disorder

• Current or past history of seizures

• Any metal implants

• Mini Mental Status Examination score of less than 20

• Diagnosis of bipolar disorder or current Major depression episode

• Electroconvulsive Therapy (ECT) within 6 months

• Varenicline hypersensitivity.

Study Design

Allocation: Randomized, Intervention Model: Crossover Assignment, Masking: Double Blind (Subject, Investigator)

Related Conditions & MeSH terms

• Schizophrenia

Intervention

Drug:
• Varenicline
Champix (Varenicline) is an approved smoking cessation medication
• Placebo

Locations

Country	Name	City	State
Canada	Centre for Addiction and Mental Health	Toronto	Ontario

Sponsors (2)

Lead Sponsor	Collaborator
Centre for Addiction and Mental Health	Pfizer

Country where clinical trial is conducted

Canada, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Change of Paired Associative Stimulation (PAS) induced plasticity from baseline		Day 3 of weeks 1 and 2	No
Secondary	Change of Working memory performance from baseline		Day 3 of weeks 1 and 2	No

External Links

•   Centre for Addiction and Mental Health Research